New anti-epileptic drugs for the 21st century

Bibliography

• HAUSER WA, ANNEGERS JF, KURLAND LT: Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia (1993) 34(3):453–468.
   PubMed Web of Science ®Google Scholar
• MATTSON RH, CRAMER JA, COLLINS JF et al.: Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures. N. Engl. J. Med. (1985) 13:145–151.
   Google Scholar
• WHELESS JW, VENKATARAMAN V: New formulations ofdrugs in epilepsy. Exp. Opin. Pharmacother. (1999) 1(1):49–60.
   PubMedGoogle Scholar
• LEPPIK IE, DREIFUSS FE, PLEDGER GW et al.: Felbamate for partial seizures: results of a controlled clinical trial. Neurology (1991) 41:1785–1789.
   PubMed Web of Science ®Google Scholar
• FAUGHT E, SACHDEO RC, REMLER MP et al.: Felbamate monotherapy for partial-onset seizures: an active control trial. Neurology (1993) 43:688–692.
   PubMed Web of Science ®Google Scholar
• BOURGEOIS B, LEPPIK IE, SACKELLARES JC et al.: Felbamate: a double-blind controlled trial in patients undergoing presurgical evaluation in partial seizures. Neurology (1993) 43:693–696.
   PubMed Web of Science ®Google Scholar
• THE FELBAMATE STUDY GROUP IN LENNOX-GASTAUTSYNDROME: Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N. Engl. J. Med. (1993) 328:29–33.
   PubMed Web of Science ®Google Scholar
• •Establishes efficacy of FBM in this syndrome.
   Google Scholar
• JENSEN PK: Felbamate in the treatment of Lennox-Gastaut syndrome. Epilepsia(1994)35\(Suppl. 5):554–557.
   Google Scholar
• DICHTER MA, BRODIE MJ: New antiepileptic drugs. N Engl. J. Med. (1996) 334:1583–1590.
   PubMed Web of Science ®Google Scholar
• •Overall review of incidence of aplastic anaemia and liver failure associated with FBM use.
   Google Scholar
• NATSCH S, HEKSTER YA, KEYSER A, DECKERS CLP, MEINARDI H, RENTER WO: Newer anticonvulsant drugs. Drug Saf (1997) 17(4):228–240.
   PubMed Web of Science ®Google Scholar
• US GABAPENTIN STUDY GROUP NO. 5: Gabapentin asadd-on therapy in refractory partial epilepsy: a double-blind, placebo controlled, parallel-group study. Neurology (1993) 43:2292–2298.
   PubMed Web of Science ®Google Scholar
• UK GABAPENTIN STUDY GROUP: Gabapentin in partial epilepsy. Lancet (1990) 335:1114–1117.
   PubMed Web of Science ®Google Scholar
• ANHUT H, ASHMAN P, FEUERSTEIN TJ et al.: Gabapentin (Neuronal) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. Epilepsia (1994) 35(4):795–801.
   PubMed Web of Science ®Google Scholar
• US GABAPENTIN STUDY GROUP: The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. Epilepsy Res. (1994) 18:67–73.
   PubMed Web of Science ®Google Scholar
• BRUNT J: Outcome evaluation of gabapentin as add-on therapy for partial seizures. Can. J. Neurol. Sci. (1998) 25:134–140.
   PubMed Web of Science ®Google Scholar
• MAYER T, SCHUTTE W, WOLF P, ELGER CE: Gabapentin add-on treatment: how many patients become seizure-free? Acta Neurol. Scand. (1999) 99:1–7.
   Google Scholar
• •Evaluates which patients become seizure-free with GBP therapy.
   Google Scholar
• BEYDOUN A, FISCHER J, LABAR DR et al.: Gabapentin monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. Neurology (1997) 49:746–752.
   Google Scholar
• BEYDOUN A, FAKHOURY T, NASREDDINE W, ABOU-KHALIL B: Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy. Epilepsia (1998) 39(2):188–193.
   PubMed Web of Science ®Google Scholar
• CHADWICK DW, ANHUT H, GREINER MJ et al.: A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizure. Neurology (1998) 51:1282–1288.
   PubMed Web of Science ®Google Scholar
• CHADWICK D, LEIDERMAN DB, SAUERMANN W, ALEXANDER J, GAROFALO E: Gabapentin in generalized seizures. Epilepsy Res. (1996) 25:191–197.
   PubMed Web of Science ®Google Scholar
• TRUDEAU V, MYERS S, LAMOREAUX L, ANHUT H, GAROFALO E, EBERSOLE J: Gabapentin in naive childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J. Child Neurol. (1996) 11:470–475.
   PubMed Web of Science ®Google Scholar
• BERGEY GK, MORRIS HH, ROSENFELD W et al.: Gabapentin monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. Neurology (1997) 49:739–745.
   Google Scholar
• •Establishes safety of rapid oral loading of GBP.
   Google Scholar
• GOULD HJ: Gabapentin induced polyneuropathy. Pain (1998) 74:341–343.
   PubMed Web of Science ®Google Scholar
• GIL-NAGEL A, GAPANY S, BLESI K, VILLANUEVA N, BERGEN D: Incontinence during treatment with gabapentin. Neurology (1997) 48:1467–1468.
   PubMed Web of Science ®Google Scholar
• BUETEFISCH CM, GUTIERREZ A, GUTMANN L: Choreoathetotic movements: a possible side effect of gabapentin. Neurology (1996) 46:851–852.
   PubMed Web of Science ®Google Scholar
• TALLIAN KB, NAHATA MC, LO W, TSAO CY: Gabapentinassociated with aggressive behaviour in pediatric patients with seizure. Epilepsia (1996) 37(5):501–502.
   PubMedGoogle Scholar
• GONZALEZ-SICILIA L, CANO A, SERRANO M, HERNANDEZ J: Stevens-Johnson syndrome associated with gabapentin. Am. J. Med. (1998) 105:455.
   PubMed Web of Science ®Google Scholar
• JAWAD S, RICHENS A, GOODWIN G, YUEN WC: Controlled trial of lamotrigine (Larnictal) for refrac-tory partial seizures. Epilepsia (1989) 30(3):356–363.
   PubMed Web of Science ®Google Scholar
• SCHAPEL GJ, BERAN RG, VAJDA FJE et al.: Double-blind,placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures. J. Neurol. Neurosurg. Psychiatry (1993) 56:448–453.
   PubMed Web of Science ®Google Scholar
• MATSUO F, BERGEN D, FAUGHT E et al.: Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology (1993) 43:2284–2291.
   PubMed Web of Science ®Google Scholar
• MESSENHEIMER J, RAMSAY RE, WILLMORE LI et al.: Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia (1994) 35(1):113–121.
   PubMed Web of Science ®Google Scholar
• COCITO L, MAFFINI M, LOEB C: Long-term observations on the clinical use of lamotrigine as add-on drug in patients with epilepsy. Epilepsy Res. (1994) 19:123–127.
   PubMed Web of Science ®Google Scholar
• BUCHANAN N: Lamotrigine: clinical experience in 93 patients with epilepsy. Acta Neurol. Scand. (1995): 92:28–32.
   PubMed Web of Science ®Google Scholar
• BRODIE MJ, RICHENS A, YUEN AWC: Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet (1995) 345:476–479.
   PubMed Web of Science ®Google Scholar
• REUNANEN M, DAM M, YUEN AWC: A randomised open muhicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Res. (1996) 23:149–155.
   PubMed Web of Science ®Google Scholar
• •Good comparison of LTG and CBZ in newly diagnosed epilepsy.
   Google Scholar
• GILLIAM F, VAZQUEZ B, SACKELLARES JC et al.: An active-control trial of lamotrigine monotherapy for partial seizures. Neurology (1998) 51:1018–1025.
   PubMed Web of Science ®Google Scholar
• STEINER TJ, DELLAPORTAS CI, FINDLEY U et al.: Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia (1999) 40(5):601–607.
   PubMed Web of Science ®Google Scholar
• BUONI S, GROSSO S, FOIS A: Lamotrigine in typical absence epilepsy. Brain Dev. (1999) 21:303–306.
   PubMed Web of Science ®Google Scholar
• FRANK LM, ENLOW T, HOLMES GL et al.: Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia (1999) 40(7):973–979.
   PubMed Web of Science ®Google Scholar
• BERAN RG, BERKOVIC SF, DUNAGAN FM et al.: Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy. Epilepsia (1998) 39(12):1329–1333.
   PubMed Web of Science ®Google Scholar
• ERIKSSON A-S, NERGARDH A, HOPPU K: The efficacy oflamotrigine in children and adolescents with Exp. Opin. Pharmacother. (2000) 1(4) refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia (1998) 39(5):495–501.
   Google Scholar
• MOTTE J, TREVATHAN E, ARVIDSSON JFV: Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N. Engl.J. Med. (1997) 337:1807–1812.
   PubMed Web of Science ®Google Scholar
• •Establishes efficacy of LTG in this syndrome.
   Google Scholar
• MACKAY FJ, WILTON LV, PEARCE GL, FREEMANTLE SN, MANN RD: Safety of long-term lamotrigine in epilepsy. Epilepsia (1997) 38(8):881–886.
   PubMed Web of Science ®Google Scholar
• •Good review of overall incidence of rash and other AEs.
   Google Scholar
• SCHLIENGER RG, SHAPIRO LE, SHEAR NH: Lamotrigine- induced severe cutaneous adverse reactions. Epilepsia (1998) 39\(Suppl. 7):S22–S26.
   Google Scholar
• ••Good review of severe rash associated with LTG
   Google Scholar
• BESAG FMC, BERRY DJ, POOL F, NEWBERY JE, SUBEL B:Carbamazepine toxicity with lamotrigine: pharma-cokinetic or pharmacodynamic interacation? Epilepsia (1998) 39(2):183–187.
   PubMed Web of Science ®Google Scholar
• GIDAL BE, RUTECKI P, SHAW R, MALY MM, COLLINS DM,PITTERLE ME: Effect of lamotrigine on carbamazepine epoxide/carbamazepine serum concentration ratios in adult patients with epilepsy. Epilepsy Res. (1997) 28:207–211.
   PubMed Web of Science ®Google Scholar
• FAUGHT E, WILDER BJ, RAMSAY RE et al.: Topiramateplacebo-controlled dose-ranging trail in refractory partial epilepsy using 200-, 400- and 600-mg daily dosages. Neurology (1996) 46: 1684-1690.
   Google Scholar
• •Good review of TPM efficacy and tolerability at various TPM doses.
   Google Scholar
• PRIVITERA M, FINCHAM R, PENRY J et al.: Topiramateplacebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800- and 1,000-mg daily dosages. Neurology (1996) 46: 1678-1683.
   Google Scholar
• SHARIEF M, VITERI C, BEN-MENACHEM E et al.: Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res. (1996) 25:217–224.
   PubMed Web of Science ®Google Scholar
• TASSINARI CA, MICHELUCCI R, CHAUVEL P et al.:Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia (1996) 37(8):763–768.
   PubMed Web of Science ®Google Scholar
• BEN-MENACHEM E, HENRIKSEN 0, DAM M et al.: Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia (1996) 37(0:539–543.
   Google Scholar
• KELLETT MW, SMITH DF, STOCKTON PA, CHADWICK DW: Topiramate in clinical practice: first year's postli-censing experience in a specialist epilepsy clinic. J. Neurol. Neurosurg. Psychiatry (1999) 66:759–763.
   PubMed Web of Science ®Google Scholar
• ROSENFELD WE, SACHDEO RC, FAUGHT RE, PRIVITERA M: Long-term experience with topiramate as adjunc-tive therapy and as monotherapy in patients with partial onset seizures: retrospective survey of open-label treatment. Epilepsia (1997) 38\(Suppl. 1):534–536.
   Google Scholar
• SACHDEO RC, REIFE RA, LIM P, PLEDGER G: Topiramate monotherapy for partial onest seizures. Epilepsia (1997) 38(3):294–300.
   PubMed Web of Science ®Google Scholar
• •Establishes different efficacy between high and low dose TPM therapy.
   Google Scholar
• BITON V, MONTOURIS GD, RITTER F et al.: A random- ized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology (1999) 52:1330–1337.
   PubMed Web of Science ®Google Scholar
• SACHDEO RC, GLAUSER TA, RITTER F et al.: A double- blind, randomized trial of topiramate in Lennox- Gastaut syndrome. Neurology (1999) 52:1882–1887.
   PubMed Web of Science ®Google Scholar
• •Initial pilot study showing efficacy of TPM in this syndrome.
   Google Scholar
• GLAUSER TA, CLARK PO, STRAWSBURG R: A pilot study of topiramate in the treatment of infantile spasms. Epilepsia (1998) 39(12):1324–1328.
   PubMed Web of Science ®Google Scholar
• RICHENS A, CHADWICK DW, DUNCAN JS et al.: Adjunc-tive treatment of partial seizures with tiagabine: a placebo-controlled trial. Epilepsy Res. (1995) 21:37–42.
   PubMed Web of Science ®Google Scholar
• SACHDEO RC, LEROY IW, KRAUSS GL et al.: Tiagabine therapy for complex partial seizures. Arch. Neurol. (1997) 54:595–601.
   PubMedGoogle Scholar
• KALVIAINEN R, BRODIE M, DUNCAN J et al.: A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures. Epilepsy Res. (1998) 30:31–40.
   PubMed Web of Science ®Google Scholar
• UTHMAN BM, ROWAN AJ, AHMANN PA et al.: Tiagabine for complex partial seizures. Arch. Neurol. (1998) 55:56–62.
   PubMedGoogle Scholar
• •Shows difference in efficacy with increased dosage.
   Google Scholar
• SCHACHTER SC: Tiagabine monotherapy in the treatment of partial epilepsy. Epilepsia (1995) 36\(Supp1.6):S2–S6.
   Google Scholar
• LEPPIK IE, GRAM L, DEATON R, SOMMERVILLE KW: Safety of tiagabine: summary of 53 trials. Epilepsy Res. (1999) 33:235–246.
   PubMed Web of Science ®Google Scholar
• HOUTKOOPER MA, LAMMERTSMA A, MEYER JWA et al.: Oxcarbazepine (GP 47.680): a possible alternative to carbamazepine. Epilepsia (1987) 28(6):693–698.
   Google Scholar
• VAN PARYS JAP, MEINARDI H: Survey of 260 epileptic patients treated with oxcarbazepine (Trileptal) on a named-patient basis. Epilepsy Res. (1994) 19:79–85.
   PubMed Web of Science ®Google Scholar
• FRITS ML, KRISTENSEN 0, BOAS J et al.: Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol. Scand. (1993) 87:224–227.
   Google Scholar
• DAM M, EKBERG R, LOYNING Y, WALTIMO 0, JACOBSEN K: A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res. (1989) 3:70–6.
   PubMed Web of Science ®Google Scholar
• ••Establishes similar efficacy between OXC and CBZ.
   Google Scholar
• SCHACHTER SC, VAZQUEZ B, FISHER RS et al.: Oxcarbazepine double-blind, randomized, placebo-control, monotherapy trial for partial seizures. Neurology (1999) 52:732–737.
   PubMed Web of Science ®Google Scholar
• •Establishes safety of rapid titration of OXC.
   Google Scholar
• BILL PA, VIGONIUS U, POHLMANN H et al.: A double-blind controlled clinical trials of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res. (1997) 27:195–204.
   PubMed Web of Science ®Google Scholar
• GUERREIRO MM, VIGONIUS U, POHLMANN H et al.: A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res. (1997) 27:205–213.
   PubMed Web of Science ®Google Scholar
• •Establishes similar efficacy between PHT and OXC and safety in paediatric patients.
   Google Scholar
• CHRISTE W, KRAMER G, VIGONIUS U et al.: A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res. (1997) 26:451–460.
   PubMed Web of Science ®Google Scholar
• KLITGAARD H, MATAGNE A, GOBERT J, WULFERT E: Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharm. (1998) 353:191–206.
   PubMed Web of Science ®Google Scholar
• PRIVITERA M, BRODIE M, NOHRIA V, HEMDAL P, FRENCH, J: Open-label, safety and efficacy of leveti-racetam in refractory epileptic patients. Epilepsia (1999) 40\(Suppl. 7):218–219.
   Google Scholar
• •Establishes safety and efficacy of LVT.
   Google Scholar
• SACKELLARES JC, DONOFRIO PD, WAGNER JG, ABOU-KHALIL B, BERENT S, AASVED-HOYT K: Pilot study of zonisamide (1,2-benzisoxazole-3-methanesulfonamide) in patients with refractory partial seizures. Epilepsia (1985) 26(3):206–211.
   PubMed Web of Science ®Google Scholar
• WILENSKY AJ, FRIEL PN, OJEMANN LM, DODRILL CB, MCCORMICK KB, LEVY RH: Zonisamide in epilepsy: a pilot study. Epilepsia (1985) 26(3):212–220.
   PubMed Web of Science ®Google Scholar
• SCHMIDT D, JACOB R, LOISEAU P et al.: Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res. (1993) 15:67–73.
   PubMed Web of Science ®Google Scholar
• •Establishes safety and efficacy of ZNS in partial epilepsy.
   Google Scholar
• LEPPIK IE, WILLMORE 41, HOMAN RW et al.: Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res. (1993) 14:165–173.
   Google Scholar
• KUMAGAI N, SEKI T, YAMAWAKI H et al.: Monotherapy for childhood epilepsies with zonisamide. Jpn J. Psychiatr. Neurol. (1991) 45:357–359.
   PubMedGoogle Scholar
• HENRY TR, LEPPIK IE, GUMNIT RJ, JACOBS M: Progres-sive myoclonus epilepsy treated with zonisamide. Neurology (1988) 38:928–931.
   PubMed Web of Science ®Google Scholar
• KYLLERMAN M, BEN-MENACHEM E: Zonisamide for progressive myoclonus epilepsy: long-term observa-tions in seven patients. Epilepsy Res. (1998) 29:109–114.
   PubMed Web of Science ®Google Scholar
• ••Shows efficacy of ZNS in this progressive form of epilepsy.
   Google Scholar
• SUZUKI Y, NAGAI T, ONO J et al.: Zonisamide monotherapy in newly diagnosed infantile spasms. Epilepsia (1997) 38(9): 1035–1038.
   PubMed Web of Science ®Google Scholar
• YANAI S, HANAI T, NARAZAKI 0: Treatment of infantile spasms with zonisamide. Brain Dev. (1999) 21:157–161.
   PubMed Web of Science ®Google Scholar
• ••Shows efficacy of ZNS in this syndrome.
   Google Scholar
• LEPPIK IE: Zonisamide. Epilepsia (1999) 40\(Suppl.5):S23–S29.
   Google Scholar
• EKE T, TALBOT JF, LAWDEN MC: Severe persistent visualfield constriction associated with vigabatrin. Br. Med.J. (1997) 314:180–181.
   PubMed Web of Science ®Google Scholar
• FRENCH JA, MOSIER M, WALKER S, SOMMERVILLE K,SUSSMAN N: A double-blind, placebo-controlled study of Vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology (1996) 46:54–61.
   PubMed Web of Science ®Google Scholar
• DEAN C, MOSIER M, PENRY K: Dose-response study ofvigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia (1999) 40(1):74–82.
   PubMed Web of Science ®Google Scholar
• BROWNE TR, MATTSON RH, PENRY JK et al.: Vigabatrinfor refractory complex partial seizures: multicenter single-blind study with long-term follow-up. Neurology (1987) 37:184–189.
   PubMed Web of Science ®Google Scholar
• BROWNE TR, MATTSON RH, PENRY JK et al.: Multicenterlong-term safety and efficacy study of vigabatrin for refractory complex partial seizures: an update. Neurology (1991) 41:363–364.
   PubMed Web of Science ®Google Scholar
• SIVENIUS J, YLINEN A, MURROS K, MUMFORD JP, RIEKKINEN PJ: Vigabatrin in drug-resistant partial epilepsy: a 5-year follow-up study. Neurology (1991) 41:562–565.
   PubMed Web of Science ®Google Scholar
• CHADWICK D: Safety and efficacy of vigabatrin andcarbamazepine in newly diagnosed epilepsy: a muhicentre randomised double-blind study. Lancet (1999) 354:13–19.
   PubMed Web of Science ®Google Scholar
• TANGANELLI P, REGESTA G: Vigabatrin vs. carbamazepine in newly diagnosed focal epilepsy: a randomized response conditional cross-over study. Epilepsy Res. (1996) 25:257–262.
   Google Scholar
• AICARDI J, MUMFORD JP, DUMAS C, WOOD S: Vigabatrin as initial therapy for infantile spasms: a European retrospective survey. Epilepsia (1996) 37(7):638–642.
   PubMed Web of Science ®Google Scholar
• ••Shows efficacy of drug in this syndrome, particularly withtuberous sclerosis.
   Google Scholar
• CHIRON C, DUMAS C, JAMBAQUE I, MUMFORD J, DULAC0: Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res. (1997) 26:389–395.
   PubMed Web of Science ®Google Scholar
• LEVINSON DF, DEVINSKY 0: Psychiatric adverse eventsduring vigabatrin therapy. Neurology (1999) 53:1503–1511.
   PubMed Web of Science ®Google Scholar
• DANESHVAR H, RACETTE L, COUPLAND SG, KERTES PJ,GUBERMAN A, ZACKON D: Symptomatic and asympto-matic visual loss in patients taking vigabatrin. Ophthal-mology (1999) 106:1792–1798.
   PubMed Web of Science ®Google Scholar
• •Discusses visual field defects seen in patients on VGB.
   Google Scholar
• VERSINO M, VEGGIOTTI P: Reversibility of vigabatrin-induced visual-field defect. Lancet (1999) 354:486.
   PubMed Web of Science ®Google Scholar
• KRAUSS GL, JOHNSON MA, MILLER NR: Vigabatrin-associated retinal cone system dysfunction: electrore-tinogram and ophthalmologic findings. Neurology (1998) 50:614–618.
   PubMed Web of Science ®Google Scholar
• REMY C: Clobazam in the treatment of epilepsy: areview of the literature. Epilepsia (1994) 35\(Suppl. 5):S88–S91.
   Google Scholar
• GUBERMAN A, COUTURE M, BLASCHUK K, SHERWIN A:Add-on trial of clobazam in intractable epilepsy with plasma level correlations. Can. J. Neurol. Sci. (1990) 17:311–316.
   PubMed Web of Science ®Google Scholar
• KEENE DL, WHITING S, HUMPHREYS P: Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Can. J. Neurol. Sci. (1990) 17:317–319.
   PubMed Web of Science ®Google Scholar
• MUNN R, CAMFIELD P, CAMFIELD C, DOOLEY J: Clobazam for refractory childhood seizure disorders - a valuable supplementary drug. Can. J. Neurol. Sci. (1988) 15:406–408.
   PubMed Web of Science ®Google Scholar
• SCOTT DF, MOFFETT A: The long-term effect of clobazam as adjunctive therapy in epilepsy. Acta Neurol. Scand. (1988) 77:498–502.
   PubMed Web of Science ®Google Scholar
• BUCHANAN N: Clobazam in the treatment of epilepsy: prospective follow-up to 8 years. J. Royal Soc. Med. (1993) 86:378–380.
   PubMed Web of Science ®Google Scholar
• •Reviews long-term efficacy and tolerability of CLB in various seizure types.
   Google Scholar
• SINGH A, GUBERMAN AH, BOISVERT D: Clobazam in long-term epilepsy treatment: Sustained responders versus those developing tolerance. Epilepsia (1995) 36(8):798–803.
   PubMed Web of Science ®Google Scholar
• •Reviews potential identifiers of which patients may develop tolerance to CLB.
   Google Scholar
• REDONDO P, VICENTE J, ESPANA A, SUBIRA ML, DE FELIPE I, QUINTANILLA E: Photo-induced toxic epidermal necrolysis caused by clobazam. Br. J. Dermatol. (1996) 135:999–1002.
   PubMed Web of Science ®Google Scholar
• KORN-MERKER E, BORUSIAK P, BOENIGK HE: Gabapentin in childhood epilepsy: a prospective evaluation of efficacy and safety. Epilepsy Res. (2000) 38:27–32.
   PubMed Web of Science ®Google Scholar
• APPLETON R, FICHTNER K, LAMOREAUX L et al.: Gabapentin as add-on therapy in children with refrac-tory partial seizures: a 12-week, multicentre, double-blind, placebo-controlled study. Epilepsia (1999) 40(8):1147–1154.
   PubMed Web of Science ®Google Scholar
• DUCHOWNY M, PELLOCK JM, GRAF WD et al.: A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Neurology (1999) 53:1724–1731.
   PubMed Web of Science ®Google Scholar
• SCHLUMBERGER E, CHAVEZ F, PALACIOS L, REY E, PAJOT N, DULAC 0: Lamotrigine in treatment of 120 children with epilepsy. Epilepsia (1994) 35(2):359–367.
   PubMed Web of Science ®Google Scholar
• MESSENHEIMER JA: Rash in adult and pediatric patients treated with lamotrigine. Can. J. Neurol. Sci. (1998) 25:S14–S18.
   Web of Science ®Google Scholar
• ELTERMAN RD, GLAUSER TA, WYLLIE E et al.: A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology (1999) 52:1338–1344.
   PubMed Web of Science ®Google Scholar
• ULDALL P, BULTEAU C, PEDERSEN SA, DULAC 0, MEINILD H, LASSEN LC: Single-blind study of safety, tolerability and preliminary efficacy of tiagabine as adjunctive treatment of children with epilepsy. Epilepsia (1995) 36\(Suppl. 3):5147–S148.
   Google Scholar
• BOELLNER S, MCCARTY J, MERCANTE D, SOMMERVILLE K: Pilot study of tiagabine in children with partial seizures. Epilepsia (1996) 37\(Suppl. 4):S92.
   Google Scholar
• GAILY E, GRANSTROM M, LIUKKONEN E: Oxcarbazepine in the treatment of early childhood epilepsy. J. Child Neurol. (1997) 12:496–498.
   PubMed Web of Science ®Google Scholar
• ZAMPONI N, CARDINALI C: Open comparative long-term study of vigabatrin vs. carbamazepine in newly diagnosed partial seizures in children. Arch. Neurol. (1999) 56:605–607.
   Google Scholar
• BELANGER S, COULOMBE G, CARMANT L: Role of vigaba-trin and lamotrigine in treatment of childhood epileptic syndromes. Epilepsia (1998) 39(8):878–883.
   PubMed Web of Science ®Google Scholar
• SHETH RD, RONEN GM, GOULDEN KJ, PENNEY S, BODENSTEINER JB: Clobazam for intractable pediatric epilepsy. J. Child Neurol. (1995) 10:205–208.
   PubMed Web of Science ®Google Scholar
• CANADIAN STUDY GROUP FOR CHILDHOOD EPILEPSY: Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia (1998) 39(9):952–959.
   PubMed Web of Science ®Google Scholar
• GUERRINI R, DRAVET C, GENTON P, BELMONTE A, KAMINSKA A, DULAC 0: Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia (1998) 39(5):508–512.
   PubMed Web of Science ®Google Scholar
• GUERRINI R, BELMONTE A, PARMEGGIANI L, PERUCCA E: Myoclonic status epikpticus following high-dosage lamotrigine therapy. Brain Dev. (1999) 21:420–424.
   PubMed Web of Science ®Google Scholar
• ECKARDT KM, STEINHOFF BJ: Nonconvulsive status epilepticus in two patients receiving tiagabine treatment. Epilepsia (1998) 39(6):671–674.
   PubMed Web of Science ®Google Scholar
• ETTINGER AB, BERNAL OG, ANDRIOLA MR et al.: Two cases of nonconvulsive status epikpticus in associa-tion with tiagabine therapy. Epilepsia 40(8):1159–1162.
   Google Scholar
• PANAYIOTOPOULOS CP, AGATHONIKOU A, SHAROQI IA, PARKER APJ: Vigabatrin aggravates absences and absence status. Neurology (1997) 49:1467.
   PubMed Web of Science ®Google Scholar
• MARCIANI MG, GIGLI GL, MASCHIO MCE et al.: Vigabatrin-induced myoclonus in four cases of partial epilepsy. Epilepsia (1995) 36\(Suppl. 3):S107.
   Google Scholar
• ROGERS D, BIRD J, EAMES P: Complex partial status after starting vigabatrin. Seizure (1993) 2:155–156.
   PubMedGoogle Scholar
• PERUCCA E, GRAM L, AVANZINI G, DULAC 0: Antiepi-leptic drugs as a cause of worsening seizures. Epilepsia (1998) 39(1):5–17.
   PubMed Web of Science ®Google Scholar
• ••Good review of seizure exacerbation related to AED use. MORELLO CM, LECKBAND SG, STONER CP, MOORHOUSE DF, SAHAGIAN GA: Randomized double-blind study comparing the efficacy of gabapentin with amitrip-tyline on diabetic peripheral neuropathy pain. Arch. Intern. Med. (1999) 159:1931–1937.
   Google Scholar
• MORELLO CM, LECKBAND SG, STONER CP, MOORHOUSE DF, SAHAGIAN GA: Randomized double-blind study comparing the efficacy of gabapentin with amitrip-tyline on diabetic peripheral neuropathy pain. Arch. Intern. Med. (1999) 159:1931–1937.
   PubMed Web of Science ®Google Scholar
• BACKONJA M-M: Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: a multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus. Epilepsia (1999) 40\(Suppl. 6):S57–S59.
   Google Scholar
• MCELROY SL, SOUTULLO CA, KECK PE, KMETZ GF: A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. Ann. Clin. Psychiatry (1997) 9:99–103.
   PubMedGoogle Scholar
• BENNETT J, GOLDMAN WT, SUPPES T: Gabapentin for treatment of bipolar and schizoaffective disorders. J. Clin. Psychopharmacol. (1997) 17:141–142.
   PubMed Web of Science ®Google Scholar
• MELLICK GA, MELLICK LB: Management of restless legs syndrome with gabapentin (Neurontin). Sleep (1996) 19:224–226.
   PubMed Web of Science ®Google Scholar
• EHRENBERG BL, MULLER-SCHWARZE A, FRANKEL F: Open-label trial of gabapentin for periodic limb movements disorder of sleep. Neurology(1997) 48:A278.
   Web of Science ®Google Scholar
• GIRONELL A, KULISEVSKY J, BARBANOJ M, LOPEZ-VILLEGAS D, HERNANDEZ G, PASCUAL-SEDANO B: A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. Arch. Neurol. (1999) 56:475–480.
   PubMed Web of Science ®Google Scholar
• MAGNUS L: Nonepikptic uses of gabapentin. Epilepsia (1999) 40\(Suppl. 6):S66–S72.
   Google Scholar
• •Good review of other potential uses of GBP.
   Google Scholar
• SUPPES T, BROWN ES, MCELROY SL et al.: Lamotrigine for the treatment of bipolar disorder: a clinical case series. J. Affect. Disord. (1999) 53(1):95–98.
   PubMed Web of Science ®Google Scholar
• BOWDEN CL, CALABRESE JR, MCELROY SL et al.: The efficacy of lamotrigine in rapid cycling and non-rapid cycling patients with bipolar disorder. Biol. Psychiatry (1999) 45(0:953–958.
   PubMedGoogle Scholar
• •Establishes efficacy of LTG in bipolar disorders.
   Google Scholar
• CALABRESE JR, BOWDEN CL, SACHS GS et al.: A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depres-sion. J. Clin. Psychiatry (1999) 60:79–88.
   PubMed Web of Science ®Google Scholar
• WHEELER SD, CARRAZANA EJ: Topiramate-treated cluster headache. Neurology (1999) 53:234–236.
   PubMed Web of Science ®Google Scholar
• •Initial pilot study showing efficacy of TPM in cluster headache.
   Google Scholar
• BAJWA ZH, SAMI N, WARFIELD CA, WOOTTON J: Topira-mate relieves refractory intercostal neuralgia. Neurology (1999) 52:1917.
   PubMed Web of Science ®Google Scholar
• MARCOTTE D: Use of topiramate, a new anti-epileptic as a mood stabilizer./ Affect. Disord.(1998) 50:245–251.
   PubMed Web of Science ®Google Scholar
• NORMANN C, LANGOSCH J, SCHAERER LO, GRUNZE H, WALDEN J: Treatment of acute mania with topiramate. Am. J. Psychiatry (1999) 156:2014.
   PubMed Web of Science ®Google Scholar
• SCHAFFER LC, SCHAFFER CB: Tiagabine and the treatment of refractory bipolar disorder. Am. J. Psychiatry (1999) 156:2014–2015.
   PubMed Web of Science ®Google Scholar
• GRUNZE H, ERFURTH A, MARCUSE A, AMANN B, NORMANN C, WALDEN J: Tiagabine appears not to be efficacious in the treatment of acute mania. J. Clin. Psychiatry (1999) 60:759–762.
   PubMed Web of Science ®Google Scholar
• MELDRUM BS, CHAPMAN AG: Basic mechanisms of Gabitril (tiagabine) and future potential develop-ments. Epilepsia (1999) 40\(Suppl. 9):52–56.
   Google Scholar
• ZAKRZEWSKA JM, PATSALOS PN: Oxcarbazepine: a new drug in management of intractable trigeminal neuralgia. J. Neurol. Neurosurg. Psychiatry (1989) 52:472–476.
   PubMed Web of Science ®Google Scholar
• KUSHNER SA, DEWEY SL, KORNETSKY C: The irreversible y-arninobutyric acid (GABA) transarninase inhibitor y-vinyl-GABA blocks cocaine self-administration in rats. J. Pharmacol. Exp. Ther. (1999) 290:797–802.
   PubMed Web of Science ®Google Scholar
• ANDERSON GD: A mechanistic approach to antiepi-leptic drug interactions. Ann. Pharmacother. (1998) 32:554–563.
   PubMed Web of Science ®Google Scholar
• ••Good review of interactions among AEDs.
   Google Scholar
• RIVA R, ALBANI F, CONTIN M, BARUZZI A: Pharmacoki-netic interactions between antiepileptic drugs: clinical considerations. Clin. Pharmacokinet. (1996) 31(6):470–493. Anti-Epileptic Drugs. Levy RH, Mattson RH, Meldrum BS (Eds.), Raven Press, New York, USA (1995). FANTTORE C, CIPOLLA G, GATTI G et al.: Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in health women. Epilepsia (1999) 40(0:783–787.
   Google Scholar
• JOHANNESSEN SI: Pharmacokinetics and interaction proffle of topiramate. Review and comparison with other newer antiepileptic drugs. Epilepsia (1997) 38\(Suppl. 1):518–23.
   Google Scholar
• RICHENS A: Pharmacokinetic and pharmacodynamic drug interactions during treatment with vigabatrin. Acta Neurol. Scand. (1999 (Suppl. 162):43–46.
   Google Scholar
• ZIFKIN B, SHERWIN A, ANDERMANN F: Phenytoin toxicity due to interaction with clobazam. Neurology (1991) 41:313–314.
   PubMed Web of Science ®Google Scholar
• TASAKI K, MINAMI T, IEIRI I et al.: Drug interactions of zonisamide with phenytoin and sodium valproate serum concentrations and protein binding. Brain Dev. (1995) 17:182–185.
   PubMed Web of Science ®Google Scholar
• SENNOUNE S, MESDJIAN E, BONNETON J, GENTON P, DRAVET C, ROGER J: Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. Ther. Drug Monit. (1992) 14:269–274.
   PubMed Web of Science ®Google Scholar
• BEGLEY CE, ANNEGERS JF, LAIRSON DR, REYNOLDS TF, HAUSER WA: Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia (1994) 35(6):1230–1243.
   PubMed Web of Science ®Google Scholar
• GRIFFITHS RI, SCHRAMMEL PN, MORRIS GL, WILLS SH, LABINER DM, STRAUSS MJ: Payer costs of patients diagnosed with epikpsy. Epilepsia (1999) 40(3):351–338.
   PubMed Web of Science ®Google Scholar
• HEANEY DC, SHORVON SD, SANDER JWAS: An economic appraisal of carbamazepine, lamotrigine, phenytoin and valproate as initial treatment in adults with newly diagnosed epilepsy. Epilepsia (1998) 3 9\(Suppl. 3):519–525.
   Google Scholar
• MARKOWITZ MA, MAUSKOPF JA, HALPERN MT: Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy. Neurology (1998) 51:1026–1033.
   PubMed Web of Science ®Google Scholar
• HEANEY DC, SANDER JWAS: Cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy. Neurology (1999) 53:657.
   PubMed Web of Science ®Google Scholar
• MARSON AG, KADIR ZA, HUTTON JL, CHADWICK DW: The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia (1997) 38(8):859–880.
   PubMed Web of Science ®Google Scholar
• •Comparison of newer AEDs using multivariant analysis.
   Google Scholar
• WONG IC: Study suggests that under a quarter of patients will still be taking the new drugs after six years. Br. Med. J. (1997) 314:603–604.
   PubMedGoogle Scholar
• DREIFUSS FE: Goals of surgery for epilepsy. In: Surgical Treatment of the Epilepsies. Engel J (Ed.), Raven Press, New York, USA (1987):31–49.
   Google Scholar
• Living with Epilepsy-Report of a Roper Poll of Patients on Quality of Life. Roper Organization, Inc., New York, USA (1992).
   Google Scholar
• MCCABE PH, MICHEL NC, MCNEW CD: Clinical efficacy of combination therapy with valproic acid and lamotrigine in intractable epilepsy: high success rate with low incidence of rash. Epilepsia (1998) 39\(Suppl. 6):49.
   Google Scholar
• SCHMIDT D: Two antiepileptic drugs for intractable epilepsy with complex-partial seizures. J. Neurol. Neurosurg. Psychiat. (1982) 45:1119–1124.
   PubMed Web of Science ®Google Scholar
• DASHEIFF RM, MCNAMARA D, DICKINSON L: Efficacy of second line antiepileptic drugs in the treatment of patients with medically refractive complex partial seizures. Epilepsia (1986) 27(2):124–127.
   PubMed Web of Science ®Google Scholar
• REYNOLDS EH: Early treatment and prognosis of epilepsy. Epilepsia (1987) 28(2):97–106.
   PubMed Web of Science ®Google Scholar
• PISANI F, DI PERRI R, PERUCCA E, RICHENS A: Interac-tion of lamotrigine with sodium valproate. Lancet (1993) 341:1224.
   PubMed Web of Science ®Google Scholar
• BRODIE MJ, YUEN AWC: Lamotrigine substitution study: evidence for synergism with sodium valproate? Epilepsy Res. (1997) 26:423–432.
   Google Scholar
• •Double-blind study showing favourable outcome with VPA/LTG combination.
   Google Scholar
• PISANI F, OTERI G, RUSSO MF, DI PERRI R, PERUCCA E, RICHENS A: The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia (1999) 40(8):1141–1146.
   PubMed Web of Science ®Google Scholar
• FERRIE CD, ROBINSON RO, KNOTT C, PANAYIOTOPOU-LOS CP: Lamotrigine as an add-on drug in typical absence seizures. Acta Neurol. Scand. (1995) 91:200–202.
   PubMed Web of Science ®Google Scholar
• FERRIE CD, PANAYIOTOPOULOS CP: Therapeutic interaction of lamotrigine and sodium valproate in intractable myoclonic epilepsy. Seizure (1994) 3:157–159.
   PubMedGoogle Scholar
• BARCS G, HALASZ P: Effectiveness and tolerance of clobazam in temporal lobe epilepsy. Acta Neurol. Scand. (1996) 93:83–93.
   Web of Science ®Google Scholar
• •Reviews efficacy of CLB in temporal lobe epilepsy.
   Google Scholar
• WIEBE S, GAFNI A, BLUME WT, GIRVIN JP: An economic evaluation of surgery for temporal lobe epilepsy. J. Epilepsy (1995) 8:227–35.
   Google Scholar
• LANGFITT JT: Cost-effectiveness of anterotemporal lobectomy in medically intractable complex partial epilepsy. Epilepsia (1997) 38(2):154–163.
   PubMed Web of Science ®Google Scholar
• SPERLING MR, SAYKIN AJ, ROBERTS FD, FRENCH JA, O'CONNOR MJ: Occupational outcome after temporal lobectomy for refractory epilepsy. Neurology (1995) 45:970–977.
   PubMed Web of Science ®Google Scholar
• ••Addresses importance of seizure control and employment.
   Google Scholar